Abstract: For controlling the condition of type 2 diabetes, a pharmaceutical including a combination of mitiglinide, a pharmacologically acceptable salt thereof or a hydrate thereof and an ?-glucosidase inhibitor such as voglibose or acarbose, and a therapeutic method using the pharmaceutical are provided. The pharmaceutical according to the present invention has an extremely strong effect of decreasing a morning fasting blood glucose level, a postprandial blood glucose level and HbA1C of a patient with type 2 diabetes, and can improve glucose spike, insulin resistance and lipid metabolism.

Abstract: An agent for the treatment of urine collection disorders associated with lower urinary tract obstructive disease, characterized by containing an indoline derivative represented by the following general formula (I): wherein R represents optionally substituted aliphatic acyl optionally having an unsaturated bond, hydroxyalkyl, aliphatic acyloxyalkyl, lower alkoxy, carboxy, lower alkoxycarbonyl, aryl(lower alkoxy)carbonyl, carbamoyl, (mono- or dialkyl)carbonyl or cyano(lower alkyl), optionally halogenated aromatic acyl, furoyl, or pyridylcarbonyl; R1 represents cyano or carbamoyl; and R2 represents lower alkyl optionally having a halogen atom, cyano group, or aryl group, or a pharmaceutically acceptable salt of the derivative. The derivative and salt are usable as an agent for the treatment of urine collection disorders associated with lower urinary tract obstructive disease.

Abstract: An agent for the prevention and/or treatment of urine collection disorders associated with lower urinary tract obstructive disease, characterized by containing an indoline derivative represented by the following general formula (I): wherein R; R1; and R2 are defined in the specification. The derivative and salt are usable as an agent for the prevention and/or treatment of urine collection disorders associated with lower urinary tract obstructive disease. Silodosin is the preferred indoline derivative.

Abstract: For controlling the condition of type 2 diabetes, a pharmaceutical including a combination of mitiglinide, a pharmacologically acceptable salt thereof or a hydrate thereof and an ?-glucosidase inhibitor such as voglibose or acarbose, and a therapeutic method using the pharmaceutical are provided. The pharmaceutical according to the present invention has an extremely strong effect of decreasing a morning fasting blood glucose level, a postprandial blood glucose level and HbA1C of a patient with type 2 diabetes, and can improve glucose spike, insulin resistance and lipid metabolism.

Abstract: The present invention provides an agent useful for the prevention of transition to surgical therapy for benign prostatic hyperplasia and the like. The present invention relates to a pharmaceutical composition for the prevention of transition to surgical therapy for benign prostatic hyperplasia, which comprises an indoline derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof (in the formula, R represents an optionally substituted aliphatic acyl group, a hydroxyalkyl group, an aliphatic acyloxyalkyl group, a substituted lower alkyl group, an optionally substituted aromatic acyl group, a furoyl group, a pyridylcarbonyl group or the like; R1 represents a cyano group or a carbamoyl group; and R2 represents an optionally substituted lower alkyl group).

Abstract: A pressure fuel pump device for use with an internal combustion engine comprises a pump body which has therein first and second chambers which are aligned and merged A cylinder member is installed in the pump body. A plunger is reciprocatively movably disposed in the cylinder member to define in the cylinder member a pump chamber which is connected to both a fuel supply pump and fuel injectors through respective fuel passages. The plunger has one end exposed to the first chamber. A drive shaft is adapted to be rotated about its axis by an external power means. A rotation cam is provided on the drive shaft to rotate therewith. The end of the plunger is arranged to be pushed by the rotation cam upon rotation of the rotation cam. A bearing is disposed in the second chamber to rotatably support the drive shaft relative to the pump body.

Abstract: An axial plunger pump includes an auxiliary plate mounted to a cam plate at an end thereof on the side of a cylinder block to be rotatabe relative to the cam plate, and a flexible partition member interposed between a housing and the auxiliary plate to cover a drive shaft and the cam plate. The flexible partition member, which is in the form of, e.g. a metal bellows, serves to divide the inside of the housing into a working fluid chamber and a lubricant chamber.

Abstract: A variable capacity type vane pump comprising a cam ring, a rotor placed for rotation within the cam ring. The rotor has a number of radial slots, and vances placed for radial inward and outward movement in the receptive slots each having a bottom. A pump chamber is defined between the cam ring and the rotor and it has an inlet and outlet port. The outlet port is connected through a conduit to the bottom of at least one of the slots having vanes moving inwardly in the respective slots. A restriction orifice is placed in the conduit. The cam ring is moved with respect to the rotor to vary the capacity of the vane pump in response to a pressure differential across the restriction orifice.